We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics


Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics"

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
 

NuVasive, Inc.  has announced that it has signed a definitive agreement to acquire the Osteocel biologics business from Osiris Therapeutics, Inc. The Osteocel business includes a proprietary adult stem cell bone graft product containing beneficial properties similar to autograft, as well as a processing facility with significant supply stream capacity.

Under the terms of the agreement, NuVasive will acquire the Osteocel biologics business from Osiris for $35 million in cash at closing, plus additional milestone-based contingent payments not to exceed $50 million in either cash or a combination of cash and stock, at the Company's election.

The purchase price will be funded out of available cash and the transaction is not subject to financing conditions. The Company presently anticipates that the closing will occur in the third quarter of 2008, subject to Osiris stockholder approval and customary regulatory approvals.

Advertisement